Zevra Therapeutics Announces Resubmission Of Arimoclomol New Drug Application To The U.S. Food And Drug Administration
Read the full statement from Zevra Therapeutics here:
Here is a summary of the article:
Zevra Therapeutics Resubmits NDA for Arimoclomol: Zevra is a rare disease therapeutics company that has developed arimoclomol, an investigational drug for the treatment of Niemann-Pick disease type C (NPC), a genetic and fatal neurological disorder.
Arimoclomol Addresses Lysosomal Dysfunction in NPC: Arimoclomol is designed to improve the function of lysosomes, which are cellular compartments that transport and metabolize lipids.
Zevra Expects FDA Review within Six Months: Zevra resubmitted its NDA for arimoclomol on December 22, 2023 , after receiving a complete response letter from the FDA in June 2023.
Zevra Prepares for Commercial Launch of Arimoclomol: Zevra is accelerating its launch preparations in anticipation of FDA approval and aims to bring arimoclomol to the NPC community as soon as possible.
To join our fight, as well as fund vital research for a cure, support the Australian NPC Disease Foundation in its goals of "Research. Cure. Persevere."
Ways to support NP-C in Australia:
Check out upcoming events
Shop at our online NPC store
Fundraise your way! Check our free resources and inspo online.
Comments